Open in interactive viewer → charts, metric popovers & call review

Sonova Raised Guidance. It Also Admitted Why.

A market-driven upgrade, a lost retail customer baked into H2, and a third year of deferred buybacks
SOON.SW · Earnings Call · 2026-11-12

The headline is genuinely good

Sonova's first half of FY2026/27 is, by any ordinary reading, a strong print. Group sales reached CHF 1.8 billion, up 7.5% in local currencies, with organic growth contributing 7 percentage points and M&A only 0.5. Core EBIT rose 22.9% to CHF 384 million and the core EBIT margin expanded 260 basis points to 20.9%. Hearing instruments grew 9% with core EBIT up 26% and margin at 22.0%. Wholesale grew 11% — double digits for twelve months and, by management's count, eleven consecutive quarters of year-on-year share gaining, taking tracked-market share from the mid-20s to the low 30s percent. Retail grew around 7%, more than 5% of it organic, accelerating in the second quarter. Operating free cash flow jumped to CHF 287 million from CHF 90 million, ROCE moved to 20.9% from 19.5%, and net debt to EBITDA sat at 1.1x. So the guide went up: sales growth of 6% to 8% (was 5% to 8%) and core EBIT growth of 10% to 13% (was 7% to 10%). “Against this background, we now expect consolidated sales growth of 6% to 8% compared with 5% to 8% previously. And we are also raising our core EBIT growth guidance to 10% to 13% compared with 7% to 10% previously.” — Elodie Carr-Cingari, Chief Financial Officer (CFO) · 2026-11-12 The interesting part is why.

The upgrade belongs to the market, not to Sonova

Analysts pressed exactly this point, and the answer was refreshingly blunt. The bottom end of the sales range rose because the market assumption rose — from 2% to 4% up to 3% to 5% — not because share momentum surprised to the upside. Management then went further and pre-announced its own deceleration: the fiscal Q2 market was extraordinary, aided by a stocking effect in the channel that was explicitly not Sonova's. “About stocking effect, yes, there has been some stocking effects but not from Sonova and there was no specific push or creativity around optimizing the end of the quarter.” — Eric Bernard, Chief Executive Officer (CEO) · 2026-11-12 That is an unusually honest admission — it tells you H2 compares against a flattered base, and that the raised guidance is a market call dressed as a company call. Note the contrast with May, when the message was acceleration: “If you look at the very recent months, we're getting closer to 4%.” — Eric Bernard, Chief Executive Officer (CEO) · 2026-05-18 They got there faster than planned, and are now deliberately guiding below the achieved run rate. Fine. But it means the quality of the beat rests almost entirely on operating execution, not demand.

The sentence that matters most

Buried in a Q&A answer about wholesale cadence is the single most consequential line on the call, and it is a structural revenue leak rather than a cyclical one.

I mentioned the fact that our Italian colleagues are likely to source from our Danish colleagues, so we will see a drop in revenues out of that.

Eric Bernard, Chief Executive Officer (CEO) · 2026-11-12
Translation: Amplifon is acquiring GN Hearing, and a large retail account Sonova supplies will migrate its sourcing to the combined group. Management pegged it as low single-digit percentage of sales (an analyst guessed as much and was not corrected), said it was already baked into guidance, and framed H2 as a period where Sonova still gains share despite it. That is a genuinely company-unique negative, and it is the kind of consolidation arithmetic that defines the current M&A cycle in hearing care. The contrast with six months ago is the story. In May, the same merger was treated as a non-event leaning positive: “So we don't expect a significant impact in the coming year. I would say also that this type of acquisition or merger could create opportunities.” — Eric Bernard, Chief Executive Officer (CEO) · 2026-05-18 It has now moved from theory to the P&L. Sonova is not losing a market, it is losing a customer — and customers are harder to replace than markets.

Cochlear implants: a proof point with an American asterisk

CI sales fell 10%, with systems down 3% and upgrades down 27% — the mechanical consequence of a platform that had gone stale. Eric Bernard did not hide it: “So first half was obviously not satisfactory, minus 10%, but very much in line with our expectations.” — Eric Bernard, Chief Executive Officer (CEO) · 2026-11-12 Integro, launched in Europe mid-October and now in 18 countries, is the first real new platform in the franchise and shares Phonak's processing, microphone and connectivity technology — including the real-time AI pushed into the Roger On Sphere microphone. The problem is timing and geography. US launch remains subject to regulatory approval, and Bernard conceded it "may have an impact on our ability to generate positive growth for the full year." That is a softer line than a year ago, when the same question got a flat yes on positive CI growth for the fiscal year — and softer than May's framing of an H2 lift from the processor. The prior-call context makes the durability question sharper still:

Our latest innovation was brought to market in 2021. So we are slow to innovate versus our competition.

Eric Bernard, Chief Executive Officer (CEO) · 2025-11-15
Integro fixes the cadence. It does not yet fix the calendar.

Capital allocation: the buyback that keeps not happening

Leverage is 1.1x, inside the 1x–1.5x corridor, with CHF 266 million of free cash flow in the half. Yet the answer on buybacks was a polite no: “We are currently holding back on starting any new buyback for this fiscal year, as we have previously communicated back in May.” — Elodie Carr-Cingari, Chief Financial Officer (CFO) · 2026-11-12 Some CHF 50 million has gone into retail bolt-ons by October against an CHF 80–100 million annual ambition, and the language on pipeline — plenty of opportunities coming across the desk — is doing a lot of work. Investors who remember the earlier framing that a sub-1.5x leverage ratio would mechanically open the door to repurchases now have another year of deferral to price. There is a plausible reason: the March strategy reset committed CHF 50 million to operations to reach CHF 90 million of annualised savings, plus low-double-digit CHF million of extra investment in H2 across R&D, manufacturing and the consumer journey. Those are classified as strategic investments, and the CFO was explicit that part of the margin story is reinvestment rather than maximisation.

What management stopped saying

The keyword trail is unusually revealing this quarter. Product names churn violently — Infinio Ultra and Virto R dominated earlier quarters, now EON, Integro and Roger On Sphere carry the narrative, and the mechanical improvement is on-time fulfilment above 95% versus 64% at the Infinio launch. Price is not the constraint: when innovation is tangible, management argued, price has not been a problem in either wholesale or retail, and ASPs are trending the right way. But the loudest silence is Consumer Hearing, which was a top-three theme as recently as last year and has now vanished from the conversation entirely — reclassified as discontinued operations, carrying a CHF 68 million impairment and a CHF 57 million after-tax loss. Divestment is on track. The strategic debate that consumed multiple calls has been resolved by subtraction. What replaced it is Asia Pacific, now quantified rather than aspirational: 11.4% regional growth, mid-teens wholesale, Japan above 20%, and an explicit Phase 1 / Phase 2 framing where the next step is products designed for local price points and simpler fitting. And fair share at the large US warehouse account has finally been reached — north of 20%, with five suppliers now in the channel and Costco described as clear that everyone must be competitive and on time.

The verdict

A company executing well, on a better market, with a raised guide and a balance sheet that could do more. The two things to watch are not in the headline: whether a lost retail customer and a delayed US CI approval together shave enough off H2 to matter, and whether a third consecutive year of deferred buybacks starts to look like a policy rather than a phase.